StockNews.AI
ICU
StockNews.AI
148 days

SeaStar Medical to Report Fourth Quarter and Year-End 2024 Financial Results on March 27, 2025

1. SeaStar Medical will report Q4 and year-end 2024 results on March 27. 2. The company’s first product, QUELIMMUNE, was FDA approved in 2024. 3. SCD therapy has Breakthrough Device Designation for four conditions. 4. Ongoing pivotal trial targets adult acute kidney injury patients. 5. AKI affects over 200,000 adults annually in the U.S.

4m saved
Insight
Article

FAQ

Why Bullish?

The upcoming earnings report and product approvals highlight strong growth potential. Historical precedents show that positive FDA news often boosts stock prices significantly.

How important is it?

The announcement impacts investor sentiment and stock valuation given the FDA approval and upcoming results. Positive earnings or little-to-no losses from the pivotal trial could significantly enhance ICU’s stock prospects.

Why Short Term?

The financial results report is imminent, which could lead to immediate market reactions. Similar instances in the past have caused notable share price increases upon report disclosures.

Related Companies

NDAQAMGNRMDVRTX
March 24, 2025 17:30 ET  | Source: SeaStar Medical DENVER, March 24, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that it will report its fourth quarter and year-end 2024 financial results after market close on Thursday, March 27, 2025, and host a webcast and conference call to discuss its financial results and business progress. Date/Time:Thursday, March 27, at 4:30 p.m. ET / 1:30 p.m. PT  Webcast:The live webcast and replay can be found here.  Conference ID:2078693  Dial-in numbers:1 (800) 715-9871 within the U.S.   1 (646) 307-1963 from outside the U.S.   A replay of the call will be available after 7:30 pm ET and can be accessed as follows: The webcast replay is available here.The call replay number is 1 (609) 800-9909 and will be available through April 3, 2025. About SeaStar Medical SeaStar Medical is a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life. SeaStar’s first commercial product, QUELIMMUNE (SCD-PED), was approved in 2024 by the U.S. Food and Drug Administration (FDA). It is the only FDA approved product for the ultra-rare condition of life-threatening acute kidney injury (AKI) due to sepsis or a septic condition in critically ill pediatric patients. SeaStar’s Selective Cytopheretic Device (SCD) therapy has been awarded Breakthrough Device Designation for four therapeutic indications by the FDA, enabling the potential for a speedier pathway to approval and preferable reimbursement dynamics at commercial launch. The company is currently conducting a pivotal trial of its SCD therapy in adult patients with AKI requiring continuous renal replacement therapy, a life-threatening condition with no effective treatment options that impacts over 200,000 adults in the U.S. annually. For more information visit www.seastarmedical.com or visit us on LinkedIn or X. Contact:SeaStar Investor Relations: IR@SeaStarMed.com

Related News